Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;12(10):2732-2743.
doi: 10.1016/j.jaip.2024.04.026. Epub 2024 Apr 23.

Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness

Xingnan Li  1 , Paul Newbold  2 , Rohit Katial  3 , Ian Hirsch  2 , Huashi Li  1 , Ubaldo J Martin  2 , Deborah A Meyers  4 , Eugene R Bleecker  5
Affiliations
Free article
Clinical Trial

Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness

Xingnan Li et al. J Allergy Clin Immunol Pract. 2024 Oct.
Free article

Abstract

Background: An improved understanding of how severe asthma heterogeneity affects response could inform treatment decisions.

Objectives: Characterize heterogeneity and benralizumab responsiveness in patients grouped by predefined Severe Asthma Research Program clusters using a multivariate approach.

Methods: In post-hoc analyses of the randomized, double-blind, placebo-controlled phase III SIROCCO (NCT01928771) and CALIMA (NCT01914757) studies, patients with severe asthma who received benralizumab or placebo were assigned to clusters using an established discriminant function to analyze 11 clinical characteristics simultaneously. The annualized asthma exacerbation rate, exacerbation incidence, and lung function were analyzed across clusters.

Results: Patients (n = 2,281) met criteria for four of five clusters: cluster 2 (early-onset moderate asthma, n = 393), cluster 4 (early-onset severe asthma, n = 386), cluster 3 (late-onset severe asthma, n = 641), and cluster 5 (late-onset severe, obstructed asthma, n = 861); no patients met cluster 1 criteria. Exacerbation rate reductions were significant in late-onset severe asthma (-48% [95% CI, -61% to -31%]; P < .0001) and late-onset severe, obstructed asthma (-50% [95% CI, -59% to -38%]; P < .0001), with nonsignificant reductions in early-onset clusters. These differences could not be fully explained by blood eosinophil count differences. Values for improvements in FEV1 were significant in late-onset severe asthma (+133 mL [95% CI, 66-200]; P = .0001) and late-onset severe, obstructed asthma (+160 mL [95% CI, 85-235]; P < .0001) while maintaining acute bronchodilator responsiveness.

Conclusions: Benralizumab reduced exacerbations and improved lung function, primarily in late-onset asthma clusters. This multivariate approach to identify subphenotypes, potentially reflecting pathobiological mechanisms, can guide therapy beyond univariate approaches.

Keywords: Antiasthmatic agents; Asthma; Benralizumab; FEV; Heterogeneity; Phenotypic cluster; Respiratory hypersensitivity; Vital capacity.

PubMed Disclaimer

Publication types